Riders · Board of Pharmacy · Article VIII: Regulatory
Prescription Monitoring Program
Rider 4 in the 2026-27 Act, page VIII-44
Through the session
- 2024-25 Act In current law rider 5
- Introduced (Senate) Amended rider 4
- Introduced (House) Amended rider 4
- Senate substitute Amended rider 4
- House substitute Amended rider 4
- House passed Unchanged rider 4
- Conference Amended rider 4
- 2026-27 Act Unchanged rider 4
Pick any two steps to compare their wording.
What changed in the text
House passed → Conference: 2 passages changed.
Removed words are struck through; added words are underlined. Sources: House passed · Conference.
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | 5 | First version | — | Page VIII-39 |
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | 4 was 5 | Amended | — | Page VIII-42 |
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | 4 was 5 | Amended | — | Page VIII-42 |
| Senate substituteCommittee Substitute for Senate Bill 1 | 4 | Amended | Amended | Page VIII-39 |
| House substituteHouse Committee Substitute for Senate Bill 1 | 4 | Amended | Amended | Page VIII-39 |
| House passedSenate Bill 1 as passed the second house | 4 | Unchanged | Amended | Page VIII-39 |
| ConferenceConference Committee Report for Senate Bill 1 | 4 | Amended | Amended | Page VIII-44 |
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | 4 | Unchanged | Amended | Page VIII-44 |
Full text of each wording
Conference, 2026-27 Act
Source, page VIII-44Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to maintain Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections.
House substitute, House passed
Source, page VIII-39Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections. Included in amounts appropriated above is $225,000 in fiscal year 2026 and $150,000 in fiscal year 2027 from the Opioid Abatement Account No. 5189 to implement system enhancements related to the Prescription Monitoring Program, including an alert mechanism capable of identifying lapses in treatment for patients prescribed buprenorphine or other medications for the treatment of opioid use disorder.
Senate substitute
Source, page VIII-39Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections.
Introduced (Senate), Introduced (House)
Source, page VIII-42Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription
Monitoring Program, include $3,700,750 in fiscal year 202 6 and $3,700,750 in fiscal year 202 7
from the General Revenue Fund to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections.
2024-25 Act
Source, page VIII-39Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2024 and $3,700,750 in fiscal year 2025 in General Revenue Funds to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Sec. 2, Appropriations Limited to Revenue Collections.